Assetmark, Inc Amicus Therapeutics, Inc. Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 120,087 shares of FOLD stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

120,087

Previous 159,868 24.88%

Holding current value

$1.18 Million

Previous $1.59 Million 19.12%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$9.55 - $12.09 $379,908 - $480,952	-39,781 Reduced 24.88%	120,087 $1.28 Million
Q2 2024 Aug 13, 2024	BUY	$9.04 - $11.75 $380,231 - $494,216	42,061 Added 35.7%	159,868 $1.59 Million
Q1 2024 May 06, 2024	BUY	$11.43 - $14.24 $252,191 - $314,191	22,064 Added 23.05%	117,807 $1.39 Million
Q4 2023 Feb 09, 2024	BUY	$9.97 - $14.52 $250,067 - $364,190	25,082 Added 35.5%	95,743 $1.36 Million
Q3 2023 Oct 27, 2023	BUY	$11.78 - $13.86 $161,680 - $190,228	13,725 Added 24.11%	70,661 $859,000
Q2 2023 Aug 11, 2023	BUY	$10.72 - $13.3 $131,620 - $163,297	12,278 Added 27.49%	56,936 $715,000
Q1 2023 May 05, 2023	BUY	$10.91 - $13.54 $78,028 - $96,838	7,152 Added 19.07%	44,658 $495,000
Q4 2022 Feb 10, 2023	BUY	$9.89 - $12.7 $167,497 - $215,087	16,936 Added 82.33%	37,506 $457,000
Q3 2022 Nov 01, 2022	BUY	$9.82 - $12.75 $83,892 - $108,923	8,543 Added 71.03%	20,570 $215,000
Q2 2022 Aug 03, 2022	BUY	$6.23 - $11.12 $58,387 - $104,216	9,372 Added 352.99%	12,027 $129,000
Q1 2022 May 13, 2022	BUY	$7.89 - $12.48 $20,947 - $33,134	2,655 New	2,655 $25,000

Others Institutions Holding FOLD

# of Institutions

312

Shares Held

314M

Call Options Held

516K

Put Options Held

833K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.76B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account